Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 2948-2954

  Shah, Naman K ^a,b,c   Schapira, Allan ^d   Juliano, Jonathan J ^a   Srivastava, Bina ^c   MacDonald, Pia D M ^b,e   Poole, Charles ^b   Anvikar, Anup ^c   Meshnick, Steven R ^b   Valecha, Neena ^c   Mishra, Neelima ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL DENSITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GAMETOCYTE; HUMAN; MALARIA FALCIPARUM; MICROSCOPY; PARASITE CLEARANCE; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIA; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIMAQUINE; PYRIMETHAMINE; RECURRENCE; SULFADOXINE; YOUNG ADULT;

EID: 84879011252     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00139-13     Document Type: Article

References (43)

1. Bruce-Chwatt LJ. 1962. Classification of antimalarial drugs in relation to different stages in the life-cycle of the parasite: commentary on a diagram. Bull. World Health Organ. 27:287-290.
2. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C, Sauerwein R, Ghani AC, Drakeley C. 2010. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 9:136. doi:10.1186/1475-2875-9-136.
3. Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC. 2008. Modelling the impact of artemisinin combination therapy and longacting treatments on malaria transmission intensity. PLoS Med. 5:e226. doi:10.1371/journal.pmed. 0050226.
4. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW. 2006. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J. Infect. Dis. 193:1151-1159.
5. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ. 1994. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin. Med. J. 107:709-711.
6. Drakeley CJ, Jawara M, Targett GAT, Walraven G, Obisike U, Coleman R, Pinder M, Sutherland CJ. 2004. Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop. Med. Int. Health 9:53-61. (Pubitemid 38178012)
7. Targett G, Drakeley C, Jawara M, Von Seidlein L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, Milligan P. 2001. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J. Infect. Dis. 183:1254-1259. (Pubitemid 32281565)
8. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44:937-953.
9. Grewal RS. 1981. Pharmacology of 8-aminoquinolines. Bull. World Health Organ. 59:397-406. (Pubitemid 11024763)
10. Burgess RW, Bray RS. 1961. The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. Bull. World Health Organ. 24:451-456.
11. Gunders AE. 1961. The effect of a single dose of pyrimethamine and primaquine in combination upon gametocytes and sporogony of Laverania falcipara (Plasmodium falciparum) in Liberia. Bull. World Health Organ. 24:650-653.
12. White N. 2008. The role of anti-malarial drugs in eliminating malaria. Malar. J. 7(Suppl 1):S8. doi:10.1186/1475-2875-7-S1-S8.
13. Secretariat MPAC. 2012. Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations. Malar. J. 11:137. doi:10.1186/1475-2875-11-137.
14. Mishra N, Singh J, Srivastava B, Arora U, Shah NK, Ghosh S, Bhatt R, Sharma S, Das M, Kumar A, Anvikar A, Kaitholia K, Gupta R, Sonal G, Dhariwal A, Valecha N. 2012. Monitoring antimalarial resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010. Bull. World Health Organ. 91:1-19.
15. World Health Organization. 2009. Methods for surveillance of antimalarial drug efficacy. World Health Organization, Geneva, Switzerland.
16. Tjitra E, Suprianto S, Anstey NM. 2002. Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance. Trans. R. Soc. Trop. Med. Hyg. 96:434-437. (Pubitemid 37362032)
17. Bousema T, Drakeley C. 2011. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. 24:377-410.
18. Sharma VP. 1999. Current scenario of malaria in India. Parassitologia 41:349-353. (Pubitemid 129640275)
19. Sonal GS, Thakor HG, Joshi C, Arora P, Gupta RKD, Dhariwal AC. 2010. Epidemiological status of malaria and scaling up of interventions in India. J. Indian Med. Assoc. 108:840-843.
20. Hertz-Picciotto I, Rockhill B. 1997. Validity and efficiency of approximation methods for tied survival times in Cox regression. Biometrics 53: 1151-1156. (Pubitemid 27391042)
21. Méndez F, Muñoz Á, Plowe CV. 2006. Use of area under the curve to characterize transmission potential after antimalarial treatment. Am. J. Trop. Med. Hyg. 75:640-644. (Pubitemid 46941268)
22. Sowunmi A, Fateye BA. 2003. Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. Trop. Med. Int. Health 8:783-792. (Pubitemid 37108478)
23. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. 2009. Artemisininbased combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. 6:CD007483. doi:10.1002/14651858.CD008492.pub2.
24. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo APP, Naing AL, Nyo MY, Myint NZH, Imwong M, Ashley E, Lee SJ, White NJ. 2010. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect. Dis. 10:673-681.
25. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, Van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T. 2007. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2:e1023. doi:10.1371/journal.pone.0001023. (Pubitemid 351486737)
26. Vásquez AM, Sanín F, Alvarez LG, Tobón A, Ríos A, Blair S. 2009. Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development. Biomedica 29:307-319. (In Spanish.)
27. Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Sjafruddin D, Kusriastuti R, Hawley WA, Lobo NF, ter Kuile FO. 2013. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South Sumatra, Western Indonesia: an open label randomized controlled trial. Clin. Infect. Dis. 56:685-693.
28. Gogtay NJ, Chogle AR, Sorabjee JS, Marathe SN, Kshirsagar NA. 1999. Poor gametocytocidal activity of 45 mg primaquine in chloroquinetreated patients with acute, uncomplicated, Plasmodium falciparum malaria in Mumbai (Bombay): an issue of public-health importance. Ann. Trop. Med. Parasitol. 93:813-816. (Pubitemid 30058080)
29. Kamtekar KD, Gogtay NJ, Dalvi SS, Karnad DR, Chogle AR, Aigal U, Kshirsagar NA. 2004. A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Ann. Trop. Med. Parasitol. 98:453-458. (Pubitemid 38951678)
30. Gogtay N, Kamtekar K, Dalvi S, Mehta S, Chogle A, Aigal U, Kshirsagar N. 2006. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infect. Dis. 6:16. doi:10.1186/1471-2334-6-16. (Pubitemid 43336761)
31. Shekalaghe SA, Ter Braak R, Daou M, Kavishe R, Van den Bijllaardt W, Van den Bosch S, Koenderink JB, Luty AJF, Whitty CJM, Drakeley C, Sauerwein RW, Bousema T. 2010. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob. Agents Chemother. 054:01762-1768.
32. Baird JK, Surjadjaja C. 2011. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 27:11-16.
33. Congpuong K, Bualombai P, Banmairuroi V, Na-Bangchang K. 2010. Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria. Malar. J. 9:43. doi:10.1186/1475-2875-9-43.
34. Eziefula A, Staedke S. 2011. Evaluation of the gametocytocidal efficacy and safety of primaquine in uncomplicated falciparum malaria in Uganda. NIH Clinical Trials Registry. http://clinicaltrials.gov/show/NCT01365598.
35. Malaria Policy Advisory Committee to the WHO. 2012. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar. J. 11:424. doi:10.1186/1475-2875-11-424.
36. White NJ, Qiao LG, Qi G, Luzzatto L. 2012. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar. J. 11:418. doi:10.1186/1475-2875-11-418.
37. Lawpoolsri S, Klein EY, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford LL, Maguire JH, Smith DL. 2009. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Malar. J. 8:159. doi:10.1186/1475-2875-8-159.
38. Ouédraogo AL, Bousema T, De Vlas SJ, Cuzin-Ouattara N, Verhave Drakeley J-PC, Luty AJF, Sauerwein R. 2010. The plasticity of Plasmodium falciparum gametocytaemia in relation to age in Burkina Faso. Malar. J. 9:281. doi:10.1186/1475-2875-9-281.
39. Schneider P, Bousema JT, Gouagna LC, Otieno S, Van De Vegte-Bolmer M, Omar SA, Sauerwein RW. 2007. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am. J. Trop. Med. Hyg. 76:470-474. (Pubitemid 351627738)
40. Ouédraogo AL, Bousema T, Schneider P, De Vlas SJ, Ilboudo-Sanogo E, Cuzin-Ouattara N, Nébié I, Roeffen W, Verhave JP, Luty AJF, Sauerwein R. 2009. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One 4:e8410. doi:10.1371/journal.pone.0008410.
41. Localio AR, Berlin JA, Ten Have TR, Kimmel SE. 2001. Adjustments for center in multicenter studies: an overview. Ann. Intern. Med. 135:112-123. (Pubitemid 32661194)
42. Awono-Ambene HP, Diawara L, Robert V. 2001. Comparison of direct and membrane feeding methods to infect Anopheles arabiensis with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 64:32-34. (Pubitemid 32550095)
43. White NJ. 2013. Primaquine to prevent transmission of falciparum malaria. Lancet Infect. Dis. 13:175-181.